Table 3. Overall survival analysis of patients included in the study.
| Variable | N (%) | Median Overall Survival (months) | p (Log-Rank) |
|---|---|---|---|
| Ann Arbor Staging | |||
| I/II | 33 (39.3%) | Not reached | 0.0256 |
| III/IV | 51 (60.7%) | 24.27 | |
| IPI | |||
| 0-1 (low) | 17 (20.5%) | Not reached | 0.0236 |
| 2-3 (intermediate) | 46 (55.4%) | Not reached | |
| 4-5 (high) | 20 (24.1%) | 8.47 | |
| Hans | |||
| GCB | 39 (55.7%) | Not reached | 0.1472 |
| ABC | 31 (44.3%) | 21.6 | |
| CD68 | |||
| Low expression | 20 (24,4%) | Not reached | 0.5965 |
| High expression | 62 (75.6%) | 74.67 | |
| SPARC | |||
| Positive | 32 (47.1%) | Not reached | 0.9378 |
| Negative | 36 (52.9%) | Not reached | |
| MVD — automated counting | |||
| Quartiles I/II | 42 (50%) | Not reached | 0.0363 |
| Quartiles III/IV | 42 (50%) | 23.9 | |
| MVD — manual counting | |||
| Quartiles I/II | 40 (50%) | Not reached | 0.4041 |
| Quartiles III/IV | 40 (50%) | Not reached | |
| Stromal Signatures | |||
| Stromal-1 | 32 (44.4%) | Not reached | 0.6157 |
| Stromal-2 | 40 (55.6%) | Not reached |
The variables include: Ann Arbor staging I/II vs III/IV, IPI low vs intermediate vs high, molecular subtypes-GCB vs non-GCB or ABC, expression level of immunohistochemical markers CD68, SPARC, CD34 and stromal signatures